fashion -WSS

fashion

author：focus 2025-10-02 06:02:39 - browse：67

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Colorectal cancer study finds potential in overlooked immune cell

explore

focus

WSS

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

AI can decode, harness the power of the humane immune system

5 shark bites reported on Long Island as officials deploy surveillance drones

The future of health care in the House

2 million sign

A bus careens into a gulch in southern Mexico, leaving 27 people dead

hotspot

fashion

hotspot

Jerome Adams on the need for new antivirals for Covid

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA panel signals lack of confidence in Amgen cancer drug data

United colonoscopy coverage change 'may cost lives,' doctors say

FDA rejects Alnylam's heart disease treatment over insufficient data

Cancer drug shortages should be causing more outrage

Senate panel eyes new effort on drug shortages

BioMarin wins approval for gene therapy to treat hemophilia A

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

hotspot

Sana to lay off nearly a third of staff, de

Adele warns fans about throwing things at performers onstage

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

A Q&A with the global head of Boehringer Ingelheim's innovation unit

The future of health care in the House

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

explore

focus

focus

knowledge